For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.59 million shares were traded. OTLK stock price reached its highest trading level at $1.6894 during the session, while it also had its lowest trading level at $1.6.
Ratios:
For a deeper understanding of Outlook Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.72.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 71137280 and an Enterprise Value of 79470912.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.27, which has changed by -0.77433 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $9.25, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is -4.39%, while the 200-Day Moving Average is calculated to be -41.87%.
Shares Statistics:
For the past three months, OTLK has traded an average of 613.56K shares per day and 861400 over the past ten days. A total of 32.91M shares are outstanding, with a floating share count of 21.22M. Insiders hold about 50.49% of the company’s shares, while institutions hold 16.68% stake in the company. Shares short for OTLK as of 1749772800 were 2739054 with a Short Ratio of 4.46, compared to 1747267200 on 3153047. Therefore, it implies a Short% of Shares Outstanding of 2739054 and a Short% of Float of 7.829999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Outlook Therapeutics Inc (OTLK) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.13 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.4 and -$2.33 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$1.22, with 3.0 analysts recommending between -$0.95 and -$1.55.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $6.51M. There is a high estimate of $8.7M for the next quarter, whereas the lowest estimate is $3M.
Based on 5 analysts’ estimates, the company’s revenue will be $34.93M in the next fiscal year. The high estimate is $50.95M and the low estimate is $17.1M.
